Last reviewed · How we verify
Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aldactone | Spironolactone | Pfizer Inc. | Potassium-sparing diuretic, aldosterone antagonist | Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia:
- Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia treatment updates — RSS
- Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia treatment updates — Atom
- Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/long-term-maintenance-therapy-for-bilateral-micro-or-macronodular-adrenal-hyperplasia. Accessed 2026-06-10.
Related
- Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing